Login
$KLRA
$12.68 -$0.59 (4.48%) Live

Company Executives

Management Team

From Forms 3, 4 and 5 filed in the last 18 months
Officer Source
Ronald C Renaud JR
CEO & President
Title from the Form 4 dated Jun 9, 2026
Douglas W. Pagan
Chief Financial Officer
Title from the Form 4 dated Apr 16, 2026
Nur Nicholson
Chief Technology Officer
Title from the Form 4 dated Sep 7, 2026
Scott M. Wasserman
Chief Medical Officer
Title from the Form 4 dated Apr 16, 2026
Jamie Beth Coleman
Chief Commercial Officer
Title from the Form 4 dated Apr 16, 2026
Scott Akamine
Chief Legal Officer
Title from the Form 4 dated Apr 16, 2026
Paula Cloghessy
Chief People Officer
Title from the Form 4 dated Apr 16, 2026
Kathleen Tregoning
See Remarks
Title from the Form 4 dated Jul 6, 2026
Paul D. Burgess
See Remarks
Title from the Form 4 dated Apr 16, 2026

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

No proxy statement on record

Board of Directors comes from the company’s proxy statement. Kailera Therapeutics, Inc. has not filed one with the SEC.

No proxy statement on record

Related-party transactions come from the company’s proxy statement. Kailera Therapeutics, Inc. has not filed one with the SEC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support